The recent decline in Foghorn Therapeutics' stock was attributed to the discontinuation of another of its products, FHD-286. However, the analysts emphasized that this event does not impact their ...
The markets were closed on Monday for Martin Luther King Jr. Day, which also marked the inauguration of Donald J. Trump, the ...
B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating ...
In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...
Learn about the latest financial trends and strategies in our comprehensive article written by a financial expert.
B. Riley analyst Yuan Zhi reiterates a Buy rating on Mirion (MIR) amid concerns regarding DeepSeek. Over the weekend, reported said China’s ...
B. Riley reduced their Q1 2025 earnings per share estimates for shares of Onsemi in a report released on Friday, January 24th ...
Research analysts at B. Riley increased their FY2024 earnings estimates for FormFactor in a research note issued on Monday, January 27th. B. Riley analyst C. Ellis now forecasts that the semiconductor ...
Chairman Bryant Riley has put a priority on paying down debt as his firm seeks to recover from a string of losses.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback